EU anti-counterfeiting law approved, but much work still to be done
This article was originally published in Scrip
The European Parliament has finally approved the directive on tackling the trade in counterfeit medicines, after several months of discussions with the Council of Ministers over the final shape of the legislation. Stakeholders including the pharmaceutical industry and wholesalers have broadly welcomed the vote, albeit with some reservations on issues such as product pack verification.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.